Cannabis Science Inc (OTCMKTS:CBIS) Finishes The Week Green

[[tagnumber 0]][[tagnumber 1]]For the most part of this year we have seen Cannabis Science Inc (OTCMKTS:CBIS) slide down the charts on quite small volumes. It couldn’t be any other way considering the company stock was heavily overpriced and the company had very little to show.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The problem is that the company is still very negligent when it comes to being up to date with its shareholders. On August 17 it filed an NT 10–K and their annual report is still not filed to this day while the numbers contained in the one covering the period ended March 31, 2015 looked pretty awful.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 9]] [[tagnumber 10]]cash: $37 thousand[[tagnumber 11]] [[tagnumber 10]]current assets: $186 thousand[[tagnumber 11]] [[tagnumber 10]]current liabilities: $3.8 million[[tagnumber 11]] [[tagnumber 10]]revenues: ZERO[[tagnumber 11]] [[tagnumber 10]]quarterly net loss: $4.34 million[[tagnumber 11]] [[tagnumber 20]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]And we see all this while the company is talking about creating shareholder value. If someone was so keen on creating shareholder value they would at least filed their reports on time and not brag about things that are simply not going to happen. You may ask what we are talking about.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The company is trying very hard to convince everyone that it is on a path to get its stock uplisted to the NASDAQ exchange. Even after Friday’s 10.56% gain, however, the ticker is sitting at [[tagnumber 28]]$0.0398 per share[[tagnumber 29]]. Good luck getting your stock listed on any national exchange with that price.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]This price was reached after some boastful press releases from the middle of last month that announced the company was going to issue dividend payouts and raise [[tagnumber 28]]$15–25 MILLION[[tagnumber 29]] in capital for drug development apart from formally pursuing the NASDAQ listing. Back then the company stock was in an even uglier position, sitting at a [[tagnumber 28]]52–week low of[[tagnumber 29]] [[tagnumber 28]]$0.013 per share[[tagnumber 29]].[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The truths is that even if [[tagnumber 28]]CBIS[[tagnumber 29]] manages to acquire such financing it will be at the cost of heavy dilution, which will push the stock’s price even further down the bottoms of the charts, leading them further and further away from a listing on a national exchange. Consider trades only after doing your due diligence and weighing out the potential risks involved in them.[[tagnumber 2]]